JWJoel Wedd

Joel Wedd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joel Wedd has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The optimal timing and management of hepatitis B and C in patients with hepatocellular carcinoma

    by Thuy-Van P. Hang, Joel P. Wedd

    The optimal timing and management of hepatitis B and C in patients with hepatocellular carcinoma Thuy-Van P. Hang, Joel P. Wedd


  • Open Access

    Racial, Ethnic, and Socioeconomic Disparities in Web-Based Patient Portal Usage Among Kidney and Liver Transplant Recipients: Cross-Sectional Study

    by Joel Wedd, Mohua Basu, Laura M Curtis, Kayla Smith, Denise J Lo, Marina Serper, Michael S Wolf, Ruth Parker, Rachel E Patzer

    Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Kidney and liver transplant recipients must manage a complex care regimen after kidney transplant. Although the use of web-based patient portals is known to improve patient-provider communication and health outcomes in chronic disease populations by helping patients manage post-transplant care, disparities in access to and use of portals have been reported. Little is known about portal usage and disparities among kidney and liver transplant recipients. Objective: The aim of this study was to examine patient demographic, clinical, and socioeconomic characteristics associated with portal usage among kidney and liver transplant recipients. Methods: The study included all adult kidney and liver transplant recipients (n=710) at a large academic transplant center in the Southeastern United States between March 2014 and November 2016. Electronic health record data was linked with Cerner portal usage data. Patient portal use was defined as any portal activity (vs. no activity) recorded in the Cerner web-based portal, including viewing of health records, lab results, medication lists, and the use of secure messaging. Multivariable log-binomial regression was used to determine the patient demographic, clinical, and socioeconomic characteristics associated with portal usage, stratified by organ. Results: Among 710 transplant recipients (n=455 kidney, n=255 liver), 55% of kidney recipients and 48% of liver recipients used the patient portal. Black patients were less likely to use the portal vs. white patients among both kidney (57% black vs. 74% white) and liver (28% black vs. 55% white) transplant recipients. In adjusted multivariable analyses, kidney transplant recipients were more likely to use the portal if they had higher education; among liver recipients, patients who were white vs. black race, and had higher education were more likely to use the portal. Conclusions: Patient portals have the potential to benefit transplant recipients as a tool for health management, but racial and socioeconomic disparities should be considered prior to widespread implementation. Transplant centers should include portal training and support to all patients to encourage use given its potential to improve outcomes.


  • Open Access

    Racial, Ethnic, and Socioeconomic Disparities in Web-Based Patient Portal Usage Among Kidney and Liver Transplant Recipients: Cross-Sectional Study (Preprint)

    by Joel Wedd, Mohua Basu, Laura M Curtis, Kayla Smith, Denise J Lo, Marina Serper, Michael S Wolf, Ruth Parker, Rachel E Patzer

    BACKGROUND Kidney and liver transplant recipients must manage a complex care regimen after kidney transplant. Although the use of Web-based patient portals is known to improve patient-provider communication and health outcomes in chronic disease populations by helping patients manage posttransplant care, disparities in access to and use of portals have been reported. Little is known about portal usage and disparities among kidney and liver transplant recipients. OBJECTIVE The aim of this study was to examine patient racial/ethnic, socioeconomic, and clinical characteristics associated with portal usage among kidney and liver transplant recipients. METHODS The study included all adult kidney and liver transplant recipients (n=710) at a large academic transplant center in the Southeastern United States between March 2014 and November 2016. Electronic medical record data were linked with Cerner portal usage data. Patient portal use was defined as any portal activity (vs no activity) recorded in the Cerner Web-based portal, including viewing of health records, lab results, medication lists, and the use of secure messaging. Multivariable log-binomial regression was used to determine the patient demographic, clinical, and socioeconomic characteristics associated with portal usage, stratified by organ. RESULTS Among 710 transplant recipients (n=455 kidney, n=255 liver), 55.4% (252/455) of kidney recipients and 48.2% (123/255) of liver recipients used the patient portal. Black patients were less likely to use the portal versus white patients among both kidney (57% black vs 74% white) and liver (28% black vs 55% white) transplant recipients. In adjusted multivariable analyses, kidney transplant recipients were more likely to use the portal if they had higher education; among liver recipients, patients who were white versus black and had higher education were more likely to use the portal. CONCLUSIONS Despite studies showing that patient portals have the potential to benefit transplant recipients as a tool for health management, racial and socioeconomic disparities should be considered before widespread implementation. Transplant centers should include portal training and support to all patients to encourage use, given its potential to improve outcomes.

  • Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin

    by A. A. Pillai, R. Maheshwari, R. Vora, J. P. Norvell, R. Ford, S. Parekh, N. Cheng, A. Patel, N. Young, J. R. Spivey, et al.

    Summary: Background: Ledipasvir and sofosbuvir is a well‐tolerated regimen with high sustained virological response (SVR) rates in pre‐liver transplant patients infected with chronic hepatitis C virus (HCV), but data in liver transplant recipients outside of clinical trials is limited.Aim: To address this knowledge gap and assess SVR rates without the use of ribavirin in liver transplant recipientsMethods: This is a retrospective study examining the treatment of 75 post‐liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Differences between SVR cohorts and predictors of SVR were analysed in an intention‐to‐treat (ITT) fashion.Results: A total of 408 genotype 1, HCV patients were treated with ledipasvir/sofosbuvir from October 2014 to August 2015 at our centre. Seventy‐three patients were post‐liver transplant and were treated with a median of 2.9 years from transplant. Ledipasvir/sofosbuvir achieved an SVR12 of 95.9%. African Americans made up 28.8% of the cohort. Sixty‐three per cent of patients were treated previously, including 13.7% of patients previously treated with direct‐acting antivirals. Only 2.7% had recurrent allograft cirrhosis, and the majority (90.4%) was on calcineurin inhibitor based immunosuppressive therapy. Approximately 82% of patients had chronic kidney disease (CKD) stage 2 or 3. In univariate logistic regression, only detectable week 8 viral load was predictive of failure to achieve SVR.Conclusion: Our data confirm excellent SVR outcomes and favourable safety and tolerability profiles with ledipasvir/sofosbuvir without ribavirin in post‐liver transplant recipients infected with HCV, despite treatment guidelines to use ribavirin.